HONG KONG, Nov. 21, 2023 /PRNewswire/ — ICZOOM Group Inc. (Nasdaq: IZM) (the "Company" or "ICZOOM"), a B2B electronic component products e-commerce platform, announced today that the Company was named to the influential 2023 China Top 100 Industrial Digitization List. ICZOOM received the prominent award along with Alibaba B2B, Ouyeel Yunshang, Guolian Co., Ltd., Huitongda, Huaneng Zhilian, Shanghai Ganglian, and other top-ranking companies.

The latest ranking was unveiled at the 10th Industrial Digitalization Conference with the theme of "New Space, New Engine, New Channel, and New Support" in Nanjing, China, where more than 300 government leaders, experts, scholars, entrepreneurs, and investors from across the country gathered to discuss the new trend of the platform economy development and industrial digital development.

ICZOOM’s CEO, Mr. Lei Xia, commented, "ICZOOM’s repeat inclusion on the influential 2023 China Top 100 Industrial Digitization List is a huge honor for all of us. This is a testament to our Company’s leadership through our electronic components e-commerce platform, and the hard work of our entire team. We continue to invest in enhancing our platform as we strive to extend our leadership through the continuous upgrading and improvement of our SaaS technology and services. We believe we have the most robust platform solution available, as we help small and micro-electronics enterprises successfully complete their digital transformation."

As one of the most intuitive modes of industrial digitalization, the platform economy is supported by a new generation of information technologies, such as big data, and artificial intelligence, which play an important role in the efficient allocation of resources, smooth economic circulation, and enabling industrial upgrading. It is estimated that China’s national industrial digital transactions will reach 21.2 trillion yuan, a year-on-year increase of 6.5%, and the level of industrial digital development has been steadily improving, with a growth rate higher than that of 4.2% of the national e-commerce transaction scale, and the momentum is still strong (source: Toby.com).

The proprietary Internet platform for the electronic components industry built by ICZOOM is positioned to benefit from this rapid growth.  ICZOOM’s comprehensive supply chain service addresses product selection, matching, order execution and delivery, intelligent warehousing, smart logistics, financing matching, SaaS services and other supply chain services for a large number of small and medium-sized batches/small and medium-sized enterprise supply and demand orders at a low service cost through online transactions and emerging technology support such as big data and artificial intelligence.

About China’s Top 100 Industrial Digitalization List

The "Top 100 Chinese Industrial Digitalization List" has been released by Toby.com since 2015. The final results of the annual selection are calculated by scientific algorithms based on several dimensions, such as corporate revenue, GMV data, profit data, listings, financing data, news dissemination data, enterprise and website traffic data, and other information publicly disclosed.

About the China Industrial Digitalization Conference

The annual China Industrial Digitalization Conference was held in Beijing in 2014, Nanchang in 2015, Shanghai in 2016, Ningbo in 2017-2019, and Nanjing in 2020-2023. It is estimated that more than 80% of the heads of industrial digital enterprises in China have participated in the conference, with the largest number exceeding 2,000 people.

About ICZOOM Group Inc.

ICZOOM Group Inc. (Nasdaq: IZM) is primarily engaged in sales of electronic component products to customers in Hong Kong and mainland China through its B2B e-commerce platform. These products are primarily used by China based small and medium-sized enterprises ("SMEs") in the consumer electronic industry, Internet of Things ("IoT"), automotive electronics and industry control segments. By utilizing latest technologies, the Company’s platform collects, optimizes and presents product offering information from suppliers of all sizes, all transparent and available to its SME customers to compare and select. In addition to the sales of electronic component products, the Company also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance. For more information, please visit the Company’s website: http://ir.iczoomex.com/index.html. 

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "should," "will," "could" and similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

Source : ICZOOM Named to Influential 2023 China Top 100 Industrial Digitalization List

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

International Thinkers Converge in Saudi Arabia for Groundbreaking Dialogue on Ethics and Communication in the Modern Age

RIYADH, Saudi Arabia, Nov. 21, 2023 /PRNewswire/ — As a key player in various industries and sectors, Saudi Arabia continues to forge ahead with its ambitious Saudi Vision 2030 goals. This year, the Kingdom takes a significant step in the realm of philosophical engagement by hosting the third annual Riyadh International Philosophy Conference from December 7th to 9th. The conference’s theme, ‘Trans-Cultural Values and Ethical Challenges in the Communicative Age’, represents a substantial highlight on the global philosophical calendar for the year 2023.

Exploring the Crossroads of Cultures: Saudi Arabia’s Riyadh International Philosophy Conference on Trans-cultural Values

Set against the backdrop of Riyadh’s diverse cultural landscape, the event is more than just a meeting of minds; it is a symbol of the Kingdom’s commitment to fostering global dialogue and understanding. This philosophy conference is a testament to Saudi Arabia’s role in creating prosperous platforms that meld cultural and intellectual thought from around the world, aligning with its vision to be a leader across diverse fields, and to guide humanity towards a future characterized by progress, development, and mutual understanding.

Attracting esteemed philosophers, historians, scientists, and artists from over 13 countries, the conference is poised to be a melting pot of ideas and perspectives. It will explore the intricacies of transculturality, tackling how we can navigate ethical challenges in a world where cultural boundaries are increasingly blurred.

This year’s discussions aim to probe the core of collective human experience, examining how cultural interactions shape identities and influence the future. The Riyadh International Philosophy Conference stands as a symbol of inclusivity, inviting a spectrum of thought to contribute to a diverse and engaging philosophical dialogue.

For more information about the conference and its schedule, please check the official website: HERE

Follow us on social media:

Twitter You Tube

Source : Exploring the Crossroads of Cultures: Saudi Arabia's Riyadh International Philosophy Conference on Trans-cultural Values

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

– Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients

– ORSERDU data reinforce its key role in the treatment of ER+, HER2- advanced or metastatic breast cancer (mBC) tumors that harbor ESR1 mutations, while showing initial data from combination trials

– ELZONRIS presentation includes updated real-world data from patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

FLORENCE, Italy and NEW YORK, Nov. 21, 2023 /PRNewswire/ — The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced today that they will present new data related to ORSERDU® (elacestrant) and ELZONRIS® (tagraxofusp-erzs) in two upcoming congresses.

ORSERDU, a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, was approved by the U.S. Food and Drug Administration in January 2023 under its priority review and fast track designation. In September 2023, ORSERDU was approved by the European Commission. 

Updated data, including a spotlight discussion on additional biomarker and clinical subgroup analyses from the Phase 3 EMERALD trial, along with new safety updates evaluating elacestrant in multiple combination settings, will be presented at the San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.

ELZONRIS was approved by the FDA in December 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve and previously-treated populations. In January 2021, ELZONRIS was approved by the European Commission. Updated data, including an oral presentation of updated real-world results in treatment-naïve patients with BPDCN demonstrating durable outcomes and a manageable safety profile leading to prolonged survival, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 9-12, 2023.

"The breadth of data on our novel oncology therapies, spanning solid tumors and hematologic malignancies, underscore our commitment to addressing significant unmet medical needs in difficult-to-treat cancers," said Elcin Barker Ergun, CEO of the Menarini Group. "At Menarini Stemline, we are dedicated to driving innovation in oncology to deliver targeted therapies that bring value to people living with cancer and to the healthcare providers who care for them."

See below for full details of the Menarini Group/Stemline Therapeutics’ upcoming presentations:

San Antonio Breast Cancer Symposium 2023 

Lead Author

Abstract Title and ID

Presentation Details

Bardia, A

Elacestrant vs standard-of-care in ER+/HER2- advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial

1576519/PS17-02

December 8, 2023

7-8am CT

Poster Spotlight Discussion

Hemisfair Ballroom 1-2

Rugo, H

ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)

1576517/PO2-05-04

December 6, 2023

5-7pm CT

Poster

Halls 2-3

Ibrahim, N

ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)

1576518/PO2-05-05

December 6, 2023

5-7pm CT

Poster

Halls 2-3

Patnaik, A

SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i* 

NA/PO3-04-13

December 7, 2023

12-2pm CT

Poster

Halls 2-3

Bellet, M

A phase 2 randomized pre-operative, window of opportunity trial investigating the effect of elacestrant with/without triptorelin in premenopausal patients with HR+/HER2- breast cancer – SOLTI-2104-PremiÈRe trial*

1580190/PO3-19-08

December 7, 202312-2pm CT

Poster

Halls 2-3

*Denotes investigator sponsored research or collaborative research.

65th American Society of Hematology (ASH) Annual Meeting 2023

Lead Author

Title and Publication Number

Session Name

Presentation Details

Angelucci et al.

Durable Outcomes with Manageable Safety Leading to Prolonged Survival with Tagraxofusp for Treatment-Naive Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Updated Results from a European Named Patient Program

Publication Number: 547

906. Outcomes Research – Myeloid Malignancies: Real-World Treatment Patterns and Outcomes

Oral Presentation

December 10, 2023

12:00 PM

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

Minetto et al.

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: An Interim Analysis of Italian GIMEMA AML2020 Trial*

Publication Number: 2918

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II

Poster Presentation

December 10, 2023

6:00 PM – 8:00 PM
San Diego Convention Center, Halls G-H

Lane et al.

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial*

Publication Number: 4277

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Poster Presentation

December 11, 2023

6:00 PM – 8:00 PM
San Diego Convention Center, Halls G-H 

Boichut et al.

Analysis of tagraxofusp activity in AML-PDC as a single agent and in combination with BCL2 inhibitors*

Publication Number: 2783

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Poster Presentation

December 10, 2023
6:00 PM – 8:00 PM

San Diego Convention Center, Halls G-H

Navarro Vicente et al.

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)*

Publication Number: 4234

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III

Poster Presentation

December 11, 2023

6:00 PM – 8:00 PM
San Diego Convention Center, Halls G-H

*Denotes investigator sponsored research or collaborative research

About the EMERALD Phase 3 Study (NCT03778931)
The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+, HER2- advanced/mBC patients. The study enrolled 478 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator’s choice of an approved hormonal agent. The primary endpoints of the study were progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. In the group of patients whose tumors had ESR1 mutations, elacestrant achieved a median PFS of 3.8 months vs 1.9 months on the SOC, and reduced the risk of progression or death by 45% (PFS HR=0.55, 95% CI: 0.39, 0.77) vs SOC.

About ORSERDU® (elacestrant)

U.S. Indication: ORSERDU (elacestrant), 345 mg tablets, is approved by the U.S. Food & Drug Administration (FDA) for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

Full prescribing information for the U.S. can be found at www.orserdu.com.

Important Safety Information, ORSERDU®

Warning and Precautions

Dyslipidemia: Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU.

Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose.

Adverse Reactions

Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each).

The most common adverse reactions (>10%), including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite (15%), diarrhea (13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%).

Drug interactions

Concomitant use with CYP3A4 Inducers and/or inhibitors: Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU.

Use in specific populations

Lactation: Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose.

Hepatic Impairment: Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B).

The safety and effectiveness of ORSERDU in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies: ELEVATE (NCT05563220); ELECTRA (NCT05386108); and ELCIN (NCT05596409). Elacestrant is also being evaluated in early breast cancer disease.

About ELZONRIS® (tagraxofusp-erzs)

U.S. Indication: ELZONRIS (tagraxofusp-erzs) is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.

Full prescribing information for the U.S. can be found at www.elzonris.com.

IMPORTANT SAFETY INFORMATION, ELZONRIS®

Boxed WARNING: CAPILLARY LEAK SYNDROME

Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended.

Warnings and Precautions

Capillary Leak Syndrome

Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with ELZONRIS. In patients receiving ELZONRIS in clinical trials, the overall incidence of CLS was 53% (65/122), including Grade 1 or 2 in 43% (52/122) of patients, Grade 3 in 7% (8/122) of patients, Grade 4 in 1% (1/122) of patients, and four fatalities (3%). The median time to onset was 4 days (range – 1 to 46 days), and all but 5 patients experienced an event in Cycle 1.

Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment with ELZONRIS, monitor serum albumin levels prior to the initiation of each dose of ELZONRIS and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability.

Hypersensitivity Reactions

ELZONRIS can cause severe hypersensitivity reactions. In patients receiving ELZONRIS in clinical trials, hypersensitivity reactions were reported in 43% (53/122) of patients treated with ELZONRIS and were Grade ≥ 3 in 7% (9/122). Manifestations of hypersensitivity reported in ≥ 5% of patients include rash, pruritus, and stomatitis. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur.

Hepatotoxicity

Treatment with ELZONRIS was associated with elevations in liver enzymes. In patients receiving ELZONRIS in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122) and Grade 4 AST elevations were reported in 3% (4/122) of patients. Elevated liver enzymes occurred in the majority of patients in Cycle 1 and were reversible following dose interruption.

Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Withhold ELZONRIS temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved.

Adverse Reactions

Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.

Please see full Prescribing Information, including Boxed WARNING.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About The Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4.4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com.

About Stemline Therapeutics Inc.

Stemline Therapeutics, Inc. ("Stemline") a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU® (elacestrant) in the U.S. and E.U., an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the U.S. and E.U. to date. Stemline also commercializes NEXPOVIO® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.

Source : Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

ADGM will host the ‘Climate Finance Action Pavilion’ and showcase its thriving climate finance ecosystem. ADGM has successfully introduced the region’s first comprehensive sustainable finance regulatory framework and environmental instruments to its capital markets framework, bringing the world’s first regulated voluntary carbon exchange, AirCarbon Exchange (ACX) under its jurisdiction. ADGM chairs the UAE Sustainable Finance Working Group (SFWG) composed of UAE regulatory authorities, Federal Ministries and exchanges.

ABU DHABI, United Arab Emirates, Nov. 21, 2023 /PRNewswire/ — Abu Dhabi Global Market (ADGM), the international financial centre of UAE’s capital, announced today its appointment as ‘Principal Climate Finance Partner’ at COP28, set to run in the UAE from 30th November to 12th December 2023. This partnership highlights ADGM’s strategic emergence as the leading climate finance hub in the region, which has been supporting capital formation and deployment as well as the creation and issuance of innovative financial products and regulations to achieve progress towards bridging an estimated USD 11 trillion of capital needed for net-zero by 2050.

As the Principal Climate Finance Partner, ADGM will be staging a series of strategic negotiations and interactive discussions across the blue and the green zones showcasing its thriving climate finance ecosystem during COP28.

Presented on the thematic day of "Finance, Trade & Gender Equality" at COP28, ADGM will also host on 4th December 2023, its sixth edition of the Abu Dhabi Sustainable Finance Forum (ADSFF) in partnership with Masdar a major initiative within, as part of the Abu Dhabi Sustainability Week platform. This year’s ADSFF holds added importance as it marks the UAE’s year of sustainability and serves as a global platform to convene influential international leaders’ commitment to addressing the USD 11 Trillion climate financing gap faced globally and representing the UAE and Abu Dhabi as a ‘Capital of Green Capital’.

The upcoming forum is set to feature high-profile C-level executives hailing from renowned global financial institutions, including JP Morgan Chase, Morgan Stanley, BNP Paribas, General Atlantic, Tikehau Capital and Euroclear, Southbridge, One Planet Sovereign Wealth Fund (OPSWF). The agenda is rich with key progress milestones, notably the unveiling of the evolving investment strategies employed by Sovereign Wealth Funds in partnership with OPSWF. Additionally, an exclusive interview will examine Abu Dhabi’s ascent as a rising capital of climate finance, accompanied by a significant announcement from the Lord Mayor of the City of London.

The event promises special insights into the ever-evolving regulatory landscape surrounding climate finance, with a dedicated focus on enhancing carbon markets and fostering innovation in financing solutions. Attendees can also anticipate a compelling interview with the President of JP Morgan Chase, shedding light on one of the world’s largest banks and its strategic approach to financing the transition. This forum is poised to deliver valuable perspectives and updates at the forefront of global finance.

Commenting on the significance of COP28 and its participation, H.E Ahmed Jassim Al Zaabi Chairman of ADGM said, "We are honoured to take on the pivotal role of Principal Climate Finance Partner at COP28, a testament to our enduring commitment to sustainable finance and environmental stewardship. The upcoming gathering of world leaders in the UAE is poised to be a decisive moment, promising to be an impactful and inclusive ‘Conference of the Parties,’ emphasising inclusivity and solutions-driven dialogue. We look forward to actively contributing to COP28’s objectives and leaving a lasting legacy in climate finance in the UAE and beyond."

ADGM’s strategic presence at COP28 represents another milestone in its ongoing contribution to sustainability-related initiatives. The international financial centre successfully introduced the region’s first comprehensive regulatory framework for Sustainable Finance, encompassing the region’s most extensive ESG disclosure requirements for relevant entities within ADGM and regulations for funds, discretionary managed portfolios, bonds and sukuks designed to accelerate the transition of the UAE to net zero greenhouse gas emissions. Another regulatory amendment last year introduced an environmental instrument as a class of financial instrument, allowing carbon offsets to come under its regulatory framework and bringing the world’s first regulated voluntary carbon exchange, AirCarbon Exchange (ACX), to Abu Dhabi.

In its efforts to build collaboration and strengthen the sustainability agenda across Abu Dhabi and the UAE, ADGM in 2019 established the UAE Sustainable Finance Working Group (SFWG) composed of UAE regulatory authorities, Federal Ministries and exchanges and continues to take the initiative for the Abu Dhabi Sustainable Finance Declaration, which has over 100 signatories.

These endeavours position ADGM’s dedication to advancing sustainable practices, building a Green Financial Centre of the future with a strong focus on environmental, social, and governance considerations.

Source : ADGM, the Region's Leading Climate Finance Hub, Announces its Role as Principal Partner at COP28

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

NORWALK, Conn., Nov. 22, 2023 /PRNewswire/ — GameChange Solar (GCS) announced that they will supply their Genius Tracker™ solar trackers for Sabanci Renewables’ Oriana Solar, a 232 MWdc project located on the Texas Gulf Coast in Victoria County.

Genius Tracker™ installation.

Genius Tracker technology helps improve energy gains with its WeatherSmart™ backtracking features and dynamic stow modes that protect the system from damage during severe weather events including hurricane-force winds, floods, and hail experienced in the Gulf Coast. The Genius Tracker solar trackers have undergone wind-tunnel tests of speeds up to 155 mph with CPP Wind.

Once complete, Genius Tracker technology paired with nearly 425,000 bifacial panels will generate power for approximately 34,000 homes with zero-carbon electricity on the ERCOT grid. It will serve load centers in the Gulf Coast region of Texas, including Houston, Corpus Christi, and Freeport.

Bechtel, a world-renowned engineering, construction, and project management firm, will design and deliver the solar project. The solar power plant features a co-located 60 MW/120 MWh battery storage system which will have a significant impact on reducing carbon emissions and advancing sustainable energy sources.

"GameChange Solar is honored to supply Genius Tracker as a key component for this notable collaboration between Bechtel and Sabanci," said Max Johnson, Director of Business Development at GCS. "Choosing a US-based supplier reinforces their dedication to bringing clean renewable energy to the region while supporting the local economy. We anticipate working on more projects with both exceptional teams in the future."

When Bechtel announced that Sabanci Renewables had selected it to deliver the project, Scott Austin, general manager of Bechtel’s Renewables & Clean Power business, said, "We’re delighted to expand our work with Sabanci to deliver a third renewable energy project for the people of Texas. We will be utilizing Bechtel’s 125 years of delivery expertise on this project, and as always, look to employ local people and suppliers to build a facility that will power communities with clean renewable energy for decades to come."

Construction is scheduled to start in early 2024 and be completed in mid-2025.

About Bechtel – Bechtel is a trusted engineering, construction and project management partner to industry and government. Differentiated by the quality of our people and our relentless drive to deliver the most successful outcomes, we align our capabilities to our customers’ objectives to create a lasting positive impact. Since 1898, we have helped customers complete more than 25,000 projects in 160 countries on all seven continents that have created jobs, grown economies, improved the resiliency of the world’s infrastructure, increased access to energy, resources, and vital services, and made the world a safer, cleaner place.  

Bechtel serves the Energy; Infrastructure; Manufacturing & Technology; Mining & Metals; and Nuclear, Security & Environmental markets. Our services span from initial planning and investment, through start-up and operations. www.bechtel.com

About Sabanci Renewables – Sabanci Renewables, a subsidiary of leading Turkish conglomerate Sabanci Holding, is a renewable energy developer in the US aiming to develop and operate a 1 GW renewable portfolio by 2025. The company focuses on utility scale solar, onshore wind and battery projects; mainly in ERCOT, MISO and PJM markets. Following the company’s establishment in June 2022, Sabanci first acquired a 272 MW project in October 2022. With Oriana Solar, the company will command more than 500 MW and will reach an important level in its initial investment plan. www.sabanci.com / Sabancı Climate Technologies.

About GameChange Solar

GameChange is a leading global provider of solar tracker solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. We have delivered over 26 GW of solar tracker and fixed tilt systems that combine fast installation, bankable quality, and unbeatable value through superior engineering, innovative design, and high-volume manufacturing. Our products enable solar panels at power plants to follow the sun’s movement across the sky and optimize plant performance while also protecting the array from damaging weather conditions.

Additionally, GameChange Solar through its GeniusBOS subsidiary is growing a portfolio of products for the broader renewable energy system.

For more information, please visit GameChange Solar.

Contact:
Lisa Andrews
Director of Marketing
GameChange Solar
[email protected]

Source : GameChange Solar Awarded 232 MW Genius Tracker™ Order with Bechtel on Texas Gulf Coast

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

FRISCO, Texas, Nov. 22, 2023 /PRNewswire/ — Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced that its subsidiary, Betters (Suzhou) Medical Co., Ltd, has received clearance from the U.S. Food and Drug Administration (the "FDA") under Section 510 (K) to begin marketing its portfolio of Microwave Ablation Systems and Disposable Microwave Ablation Needles as regulatory Class II devices in the United States.

Thyroid nodules occur among 30% to 50% of the United States population. Like most thyroid conditions, nodules are more common among women than men, with an increased incidence observed with advancing age. By the age of 60, more than half of women will have developed a thyroid nodule. Historically, treatment involving excision or therapy resulted in discomfort and inconvenience for patients. In contrast to these traditional approaches, Baird Medical has leveraged significant recent technological advances to develop a minimally invasive, thermal energy-based procedure (the "Procedure") to treat thyroid nodules, breast tumors, and other diseases for which the coagulation (ablation) of soft tissues is indicated. The Company’s approach eliminates the need for surgery, thereby mitigating associated complications, risks, and scarring for the majority of patients.

During the Procedure, therapeutic microwave energy is safely administered via a device approximately the diameter of a pen. This minimally invasive treatment precisely targets the nodule or tumor being treated, while preserving the surrounding healthy tissue. This precision is crucial, as it safeguards the function of the thyroid and reduces the likelihood that a patient will require expensive, lifelong thyroid hormone replacement therapy.  

In light of the increasing scientific evidence demonstrating positive outcomes associated with the expanded availability of the Procedure, both the American Thyroid Association and the European Thyroid Association have published recommended guidelines for the implementation and adoption of the Procedure. Physician associations, such as The North America Society for Interventional Thyroidology, have been established to raise awareness among physicians and patients that a minimally invasive solution exists for treating thyroid disease.

Ms. Haimei Wu, Founder and CEO of Baird Medical, commented, "Attaining FDA clearance represents a significant milestone in our geographical expansion. This clearance grants us the ability to market our portfolio of MWA systems and disposable needles in the United States. Based on our market research, we estimate that the U.S. presents a market opportunity of $1.6 billion for MWA systems alone. Because our follow-on sales of disposable MWA needles typically generate 36 times the revenue of our initial MWA system sales, we anticipate a total addressable market size of $1.6 billion in the U.S. alone. We are excited about our potential to capitalize on such a vast market opportunity. Our team of skilled professionals is ready to expand our market reach and deliver the much-needed benefits of our minimally invasive MWA procedure to patients across America."

About Baird Medical

Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading MWA medical device manufacturer and provider in China. Baird Medical’s proprietary medical devices are used in China for the treatment of benign and malignant tumors including thyroid nodules, liver cancer, lung cancer and breast lumps. Baird Medical is the first company to obtain a Class III medical devices registration certificate for MWA medical devices specifically indicated for thyroid nodules in China. For more information, please visit http://baidesz.com/en/. 

Forward-Looking Statements

This communication contains "forward-looking statements." Such statements include statements concerning anticipated future events and expectations that are not historical facts. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are typically identified by words such as "believe", "expect", "anticipate", "intend", "target", "estimate", "continue", "positions", "plan", "predict", "project", "forecast", "guidance", "goal", "objective", "prospects", "possible" or "potential" by future conditional verbs such as "assume", "will", "would", "should", "could" or "may" or by variations of such words or by similar expressions or the negative thereof. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors. Readers are cautioned not to rely on these forward-looking statements, which speak only as of the date on which they are made. Baird Medical does not assume any obligation to publicly update any forward-looking statement after it is made, whether as a result of new information, future events or otherwise, except as required by law.

Contacts
Investor Relations
Robin Yang, Partner
ICR, LLC
Phone: +1 (646) 308-1475
Email: [email protected]

Public Relations
Brad Burgess, Senior Vice President
ICR, LLC
Phone: +1 (646) 588-0383
Email: [email protected]

Source : Baird Medical Attains FDA Clearance to Market Its Microwave Ablation System in the United States

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING, Nov. 21, 2023 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that its multi-level feature fusion algorithm based on convolutional neural networks (CNN) can better capture the global and local information of an image and improve the performance of the model by fusing features from different levels.

Feature fusion algorithms have been widely used in computer vision, natural language processing and other fields. By fusing features of different levels or modalities, the expressive ability and performance of the model are improved to better solve complex tasks. The multilevel feature fusion algorithm studied by WiMi adopts a deep network structure, and gradually extracts the high-level features of the image through multiple convolutional and pooling operations, to better express the semantic information of the image. In addition, by fusing features at different levels, the model can focus on both global and local information about the image, thus improving the performance of the model. The multi-level feature fusion algorithm, as an improved CNN model, has important applications in the field of image processing. CNN is a deep-learning algorithm widely used in the field of computer vision. It extracts the features of an image through multilevel convolutional and pooling layers and performs classification and recognition through fully connected layers, which has the advantages of automatic learning of feature representation, parameter sharing and local perceptibility.

CNN-based multi-level feature fusion algorithms can improve the performance and generalization of the model by fusing features from different layers. A multi-layered CNN model is used which contains multiple convolutional and pooling layers and a fully connected layer for classification tasks. By fusing the features of different layers, the information of different layers can be effectively captured and the features of different layers of the image can be effectively extracted for better classification, thus improving the accuracy of the model. The application of the algorithm mainly includes the following key modules:

Feature extraction: First, the input image is feature extracted by CNN. Different levels of convolutional layers can extract features with different levels of abstraction of the image.

Feature fusion: The features at different levels are fused. Different fusion methods can be used such as weighted fusion, cascade fusion or parallel fusion. Weighted fusion can get the weight of each feature layer by learning, cascade fusion can connect features of different levels in series, and parallel fusion can process features of different levels in parallel.

Feature mapping: The fused features are mapped to further extract more discriminative features. This can be achieved using fully connected layers, pooling layers, or other nonlinear mapping functions.

Feature selection: Select the most discriminative features for further processing according to the needs of the specific task.

The multi-level feature fusion algorithm based on CNN improves the performance and generalization ability of the model by effectively extracting the multi-level features of the image and fusing them, and it has important research significance and application prospects. This algorithm has a wide range of applications in tasks such as image classification, target detection and image generation.

The current multi-level feature fusion algorithm mainly focuses on the fusion of shallow and mid-level features, and in the future, WiMi will further explore deeper feature fusion, such as the fusion of higher-level features, to improve the algorithm’s performance and expressive ability. The attention mechanism is introduced into the multilevel feature fusion algorithm to improve the network’s ability to perceive and utilize key features. In addition to CNN, other models can be considered to combine with multilevel feature fusion algorithms, such as recurrent neural networks (RNN) or graph convolutional networks (GCN), to further improve the performance and applicability of the algorithms. The performance of the multi-level feature fusion algorithm can be improved by improving the network structure, such as introducing residual connections and increasing the width and depth of the network.

The multi-level feature fusion algorithm based on CNN has been widely used in the field of computer vision, and in the future, WiMi will continue to expand to other fields, such as natural language processing, speech recognition, etc., to explore the potential and applications of multi-level feature fusion algorithms in other tasks.

About WIMI Hologram Cloud

WIMI Hologram Cloud, Inc. (NASDAQ:WIMI) is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication and other holographic AR technologies.

Safe Harbor Statements

This press release contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company’s strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission ("SEC") on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company’s expectations regarding demand for and market acceptance of its products and services.

Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement except as required under applicable laws.

Source : WiMi Announced Multi-Level Feature Fusion Algorithm Based on Convolutional Neural Networks

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHANGHAI, Nov. 21, 2023 /PRNewswire/ — Cango Inc. (NYSE: CANG) ("Cango" or the "Company"), a leading automotive transaction service platform in China, today announced that it plans to release its third quarter 2023 financial results after the market closes on Monday, November 27, 2023. The earnings release will be available on the Company’s investor relations website at http://ir.cangoonline.com/.

Cango’s management will hold a conference call on Monday November 27, 2023 at 8:00 P.M. Eastern Time or Tuesday, November 28, 2023 at 9:00 A.M. Beijing Time to discuss the financial results. Listeners may access the call by dialing the following numbers:

International:

+1-412-902-4272

United States Toll Free:

+1-888-346-8982

Mainland China Toll Free:

4001-201-203

Hong Kong, China Toll Free:

800-905-945

Conference ID:

Cango Inc.

The replay will be accessible through December 4, 2023, by dialing the following numbers:

International:                         

+1-412-317-0088

United States Toll Free:       

+1-877-344-7529

Access Code:

5256781

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at http://ir.cangoonline.com/.

About Cango Inc.

Cango Inc. (NYSE: CANG) is a leading automotive transaction service platform in China, connecting car buyers, dealers, financial institutions, and other industry participants. Founded in 2010 by a group of pioneers in China’s automotive finance industry, the Company is headquartered in Shanghai and has a nationwide network. Leveraging its competitive advantages in technological innovation and big data, Cango has established an automotive supply chain ecosystem, and developed a matrix of products centering on customer needs for auto transactions, auto financing and after-market services. By working with platform participants, Cango endeavors to make car purchases simple and enjoyable, and make itself customers’ car purchase service platform of choice. For more information, please visit: www.cangoonline.com.

Investor Relations Contact

Yihe Liu
Cango Inc.
Tel: +86 21 3183 5088 ext.5581
Email: ir@cangoonline.com
Twitter: https://twitter.com/Cango_Group

Helen Wu
Piacente Financial Communications
Tel: +86 10 6508 0677
Email: ir@cangoonline.com

Source : Cango Inc. to Report Third Quarter 2023 Financial Results on November 27, 2023 Eastern Time

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network